Steris Healthcare: Committed to Quality Healthcare and Pharmaceutical Excellence

 

Sucroferric Oxyhydroxide Chewable Tablets 2500 mg: Uses, Benefits, Dosage, Side Effects & Precautions

RUDIX SUCRO FE contains Sucroferric Oxyhydroxide Chewable Tablets 2500 mg and is marketed by Steris Healthcare. Sucroferric oxyhydroxide is an iron-based phosphate binder used primarily to control elevated phosphate levels in adults with chronic kidney disease (CKD) who are receiving dialysis. In advanced kidney disease, the kidneys may not remove phosphate efficiently, causing phosphate to accumulate in the blood. Controlling phosphate is an important part of managing CKD-mineral and bone disorder.

Unlike medicines that are absorbed into the bloodstream to produce their main effect, sucroferric oxyhydroxide works predominantly inside the gastrointestinal tract. It binds dietary phosphate after food is consumed, reducing the amount of phosphate available for absorption.

Important: RUDIX SUCRO FE should be used under medical supervision. The exact dose is individualized according to serum phosphate levels, diet, dialysis status and response to treatment.

What is Sucroferric Oxyhydroxide 2500 mg Used For?

Sucroferric oxyhydroxide is used as a phosphate binder to help control serum phosphorus in adults with chronic kidney disease on dialysis.

Healthy kidneys normally remove excess phosphate through urine. When kidney function becomes severely impaired, phosphate can accumulate. Persistently elevated phosphate may contribute to disturbances in calcium-phosphate balance and complications involving bones and blood vessels.

RUDIX SUCRO FE helps reduce dietary phosphate absorption by binding phosphate within the digestive tract.

It is generally used alongside:

• A kidney-appropriate diet
• Dialysis
• Regular blood tests
• Other CKD treatments prescribed by the nephrologist

Why is Sucroferric Oxyhydroxide Important?

Phosphate is an essential mineral involved in energy metabolism, bone structure and cellular functions. However, maintaining an appropriate phosphate balance becomes difficult when kidney function is substantially reduced.

High serum phosphate may contribute to secondary hyperparathyroidism, bone-mineral abnormalities and vascular or soft-tissue calcification in people with advanced CKD.

Phosphate binders are therefore an important component of phosphate management for selected dialysis patients.

Because sucroferric oxyhydroxide acts within the digestive tract, its principal role is to prevent phosphate from dietary sources from being absorbed.

Key Benefits 

What are the Benefits of Sucroferric Oxyhydroxide?

When prescribed appropriately, RUDIX SUCRO FE may provide the following benefits:

• Helps lower elevated serum phosphate levels.
• Binds dietary phosphate within the gastrointestinal tract.
• Reduces absorption of phosphate from food.
• Provides phosphate control as part of CKD management.
• Can be used in adults receiving dialysis when clinically indicated.
• Works locally within the gastrointestinal tract rather than depending on extensive systemic absorption.

The effectiveness of treatment should be assessed through regular serum phosphate monitoring. Dietary phosphate intake and dialysis adequacy also influence phosphate control.

Side Effects 

The most frequently reported adverse effects are gastrointestinal because the medicine works in the digestive tract.

Possible side effects include:

• Diarrhea
• Dark-colored stools
• Nausea
• Abdominal discomfort
• Constipation
• Indigestion
• Abdominal pain

Dark or black stools can occur because the medicine contains iron and may be expected. However, new or unexplained gastrointestinal bleeding should not automatically be attributed to the medicine and should be medically assessed.

Serious Side Effects

Serious adverse effects are uncommon, but seek medical attention if you develop:

• Severe or persistent abdominal pain
• Persistent vomiting
• Severe constipation
• Difficulty swallowing
• Symptoms suggesting intestinal obstruction
• Severe allergic symptoms such as facial swelling or difficulty breathing
• Unexpected gastrointestinal bleeding

Patients with significant gastrointestinal disorders may require additional caution before treatment.

Available Substitute

There are several phosphate-binding medicines, but the appropriate alternative depends on kidney function, dialysis status, calcium levels, phosphate levels, iron status, other medicines and the patient's overall treatment plan.

Potential alternatives may include:

• Sevelamer
• Lanthanum carbonate
• Calcium-based phosphate binders
• Ferric citrate
• Other phosphate-binding therapies selected by a nephrologist

These products are not automatically interchangeable. A healthcare professional should decide whether a substitute is appropriate and determine the corresponding dose.

Dosage Guidelines 

The dose of sucroferric oxyhydroxide is individualized according to the patient's serum phosphate level and response to treatment.

It is generally taken with meals, because the medicine needs to be present in the gastrointestinal tract when dietary phosphate is introduced.

The tablets are chewable and should be used according to the product's instructions. They should not be swallowed whole unless the specific product information and healthcare professional permit this.

Patients should not independently increase or decrease the dose. Serum phosphate is monitored regularly, and the healthcare professional may adjust the dose accordingly.

Precautions & Warnings

Before using RUDIX SUCRO FE, tell your healthcare professional if you have:

• Chronic kidney disease
• Dialysis treatment
• A history of gastrointestinal obstruction
• Severe gastrointestinal disease
• Difficulty swallowing
• Known iron-related disorders
• Significant abdominal symptoms
• Previous allergy to the ingredients

Tell your healthcare professional about all medicines, vitamins and supplements you take.

Because phosphate binders can interfere with absorption of some orally administered medicines, appropriate dose separation may be required for certain medicines. Follow the timing instructions provided by your doctor or pharmacist rather than assuming that all medicines can be taken together.

How to Use 

Use RUDIX SUCRO FE exactly as prescribed by your nephrologist or healthcare professional.

Important administration principles include:

1. Take the medicine with meals.
2. Chew the tablet thoroughly according to the product instructions.
3. Do not exceed the prescribed daily dose.
4. Continue the kidney-friendly diet recommended by your healthcare team.
5. Attend scheduled blood tests to monitor phosphate and other relevant parameters.
6. Follow your prescribed dialysis schedule.

If you forget a dose, do not automatically double the next dose. Follow your healthcare professional's instructions.

Mechanism of Action

Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder.

After oral administration, it remains primarily within the gastrointestinal tract. The active iron-containing complex has a strong affinity for phosphate. Dietary phosphate binds to the compound in the intestinal lumen, forming a phosphate complex that is poorly absorbed.

The bound phosphate is subsequently eliminated through the feces.

As less dietary phosphate is absorbed into the bloodstream, serum phosphate levels can decrease.

Because its main action occurs in the gastrointestinal tract, sucroferric oxyhydroxide does not work by increasing urinary phosphate excretion. This is particularly relevant in advanced CKD, where the kidneys have limited ability to eliminate phosphate.

Conclusion

Sucroferric Oxyhydroxide Chewable Tablets 2500 mg, marketed as RUDIX SUCRO FE by Steris Healthcare, are an iron-based phosphate-binding medicine used primarily to help control elevated serum phosphate in adults with chronic kidney disease who are receiving dialysis.

Its mechanism is primarily local: sucroferric oxyhydroxide binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and increasing fecal phosphate elimination. Taking the medicine correctly with meals is therefore essential to its intended action.

Successful phosphate management also depends on dietary measures, dialysis and regular laboratory monitoring. Gastrointestinal effects such as diarrhea, nausea, abdominal discomfort and dark stools may occur. Patients should report severe abdominal symptoms, persistent vomiting, significant constipation or signs of an allergic reaction.